ClinicalTrials.gg
CompletedNCT02777346Updated Jul 4, 2025

Evaluation of Emergency Suturing With Absorbable Versus Non-absorbable Suture Material in a Pediatric Population

An interventional study of Absorbable and Non absorbable in Wounds and Injuries, sponsored by Pediatric Clinical Research Platform. Completed at 1 site in Switzerland. Open to participants aged 1 Day to 16 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Pediatric Clinical Research Platform · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
1 Day to 16 Years
Sex
All
01

Study summary

The investigators recruit patients admitted to the Pediatric Emergency Department of the Geneva's University Hospital with open wounds needing suture. The patients are treated with absorbable versus non-absorbable suture material according to randomization.

Outcomes are:

  1. infection rate at the first follow-up (between 4 and 14 days, depending on the sutured site and defined by protocol)
  2. scar appearance at a 6-months follow-up.
Read the detailed description

The investigators recruit patients admitted to the Pediatric Emergency Department of the Geneva's University Hospital with open wounds needing suture. The patients are treated with absorbable versus non-absorbable suture material according to randomization.

After obtaining the patient's/parent's consent and randomization, the suture material will be provided.

Selection of the size of the thread and the date of the first follow-up are determined as follows:

  • Face: Thread size 5-0 to 7-0, first follow-up 4-7 days
  • Torso/back: Thread size 4-0 or 5-0, first follow-up 10-14 days
  • Arms: Thread size 4-0 or 5-0, first follow-up 7- 10 days
  • Hand: Thread size 5-0 or 6-0, first follow-up 7-10 days
  • Legs: Thread size 4-0 or 5-0, first follow-up 7-14 days

The patients are examined by in the outpatient wound clinic by specialised nurses under medical supervision at the first follow-up, and at six months by one of the investigators.

Outcomes:

  1. infection rate at the first follow-up (between 4 and 14 days, depending on the sutured site and defined by protocol)
  2. scar appearance at a 6-months follow-up.
02

Conditions studied

  • Wounds and Injuries

Browse trials for

Keywords

  • WOUNDS, PENETRATING
  • CHILD, PRESCHOOL
  • CHILD
  • INFANT
  • ADOLESCENT
  • SUTURES
  • POLYGLACTIN 910
  • POLYPROPYLENES
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's enrollment of 550 is above the median of 70 across 1,426 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Pediatric Clinical Research Platform is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient younger than 16 years of age with a wound requiring suture

Exclusion criteria

Exclusion Criteria:

  • Deep wounds with lesions of subcutaneous structures (tendons, nerves, etc.)
  • Wounds with tissue loss
  • Diabetic patients or patients treated with drugs potentially compromising cicatrization (e.g. , immunosuppressors, etc.)
  • Wounds caused by animal or human bites
  • Sutures not performed in the emergency room
  • Heavily soiled wounds
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
550 participants (actual)

Study arms

  • Experimental
    Absorbable

    Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).

    Device: Absorbable

  • Active comparator
    Non Absorbable

    Suture material: Polypropylene thread (Prolene®, Ethicon Inc).

    Device: Non absorbable

Interventions

  • DeviceAbsorbable

    Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups. Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments.

  • DeviceNon absorbable

    Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups. Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments.

06

What researchers measure

Primary outcomes

  1. Short-term infection risk

    Scars classified as "no evidence of infection", "signs of inflammation" and "signs of active infection"

    Time frame: 4 to 21 days

Secondary outcomes

  1. Scar appearance

    Scoring based on the Manchester scar scale

    Time frame: 6 months

07

Study locations

1 site
  • Geneva University Hospital
    Geneva, Canton of Geneva 1205, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Feb 2025, 105 months.

Of 546 non-industry interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's 105 months is above that.

Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2016
First posted
May 19, 2016
StartActual
May 2016
Primary completionActual
Feb 6, 2025
CompletionActual
Feb 6, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02777346
Lead sponsor
Pediatric Clinical Research Platform
Responsible party
Giorgio La Scala (PD, MD; Attending Surgeon, University Hospital, Geneva) — Principal investigator
First posted
May 19, 2016
Start date
May 2016
Primary completion
Feb 6, 2025
Completion
Feb 6, 2025
Last update
Jul 4, 2025

Study contacts

Giorgio La Scala, MD PD
study director · University Hospital, Geneva

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion